Naronapride dihydrochloride Drug Due Diligence Report 2026

This Naronapride dihydrochloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: HOLD / OPTION

Decision memo

Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.

The central underwriting question is whether Naronapride dihydrochloride can convert its Small molecule drug profile and 5-HT4 receptor x D2 receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Naronapride dihydrochloride (query alias: Naronapride dihydrochloride)
Modality / target	Small molecule drug; 5-HT4 receptor x D2 receptor; 5-HT4 receptor agonists, 5-HT4 receptor antagonists, D2 receptor antagonists
Highest global status	Phase 2
Originator	Renexxion LLC
Active developers	Dr. Falk Pharma GmbH, Renexxion LLC, Renexxion Ireland Ltd.

The MCP disease footprint includes Diabetic Gastroparesis, Gastroparesis, Constipation. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05621811	Phase 2	Completed	328	Primary endpoint not disclosed in English source
NCT01094821	Phase 1/2	Completed	48	Primary endpoint not disclosed in English source
NCT00630370	Phase 2	Terminated	6	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Evidence gap

The Clinical Trials MCP returned no matched public result record. This is a gating diligence gap, not evidence of failure.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Naronapride dihydrochloride addresses Diabetic Gastroparesis, Gastroparesis, Constipation. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 4 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2021-10-05	Renexxion Ireland Ltd. Announces a Licensing and Collaboration Agreement with Dr. Falk Pharma GmbH.	Phase 2	Financial terms not disclosed
2020-02-01	Renexxion , presumed to have been spun-out from Armetheon , under license from ARYx Therapeutics is developing naronapride	Phase 2	Financial terms not disclosed
2018-07-17	Sinovant Sciences and Renexxion Form Partnership to Develop Naronapride in China	Phase 2	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Material and methods for the treatment of gastro-intestinal disorders”. The milestone feed surfaced a patent-application signal described as “Methods of producing naronapride trihydrate”. The milestone feed surfaced a patent-application signal described as “Combination of Acetylcholinesterase Inhibitor and 5-HT4 Receptor Agonist As Neuroprotective Agent In the Treatment of Neurodegenerative Diseases”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

HOLD / OPTION